Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HJY28 vs Lucentis in neovascular age-related macular degeneration
CTR20212723Phase 3Completed
- Sponsor
- Huadong Medicine
- Start
- Nov 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in exudative macular degeneration, sponsored by Huadong Medicine. Started Nov 2021; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20212723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212723.